Helping humanity in the fight against cancer
According to WHO, low- and middle-income countries are more at risk to be affected by deaths due to cancer, by approximately 70%. This economic impact amplifies our importance to ensure affordability and reachability of quality medication for patients worldwide. Thus, it is imminent that we focus on expanding our largest portfolio, oncology. With advanced R&D facilities, we are capable to develop oncology APIs and formulations for regulated markets and broaden our global reach.
Our global quality oncology products are complying to USFDA & EU requirements and capable to enter stringent markets.
Prostate cancer Breast cancer Lung Cancer Blood cancer Renal cancer Colorectal cancer Ovarian & Uterine cancer Cervical cancer Thyroid cancer Liver cancer Pancreatic cancer Gastrointestinal stromal tumours (GIST) Immunosuppressants (Rheumatology & Organ Transplants) 
Our oncology plant is strategically located near the Kuala Lumpur International Airport at Enstek Park, Malaysia and holds unique features:
Built as a multiproduct commercial manufacturing facility, the facility conducts commercial cGMP manufacturing of APIs for both clinical trial supplies and commercial products for global markets, including USA. Additionally, the plant is designed for Phase-wise expansion to meet global demand of oncology APIs (Annual production capacity of 1.3 Metric ton to 15 Metric ton).
